SG11202111597UA - Methods and compositions for modulating splicing and translation - Google Patents

Methods and compositions for modulating splicing and translation

Info

Publication number
SG11202111597UA
SG11202111597UA SG11202111597UA SG11202111597UA SG11202111597UA SG 11202111597U A SG11202111597U A SG 11202111597UA SG 11202111597U A SG11202111597U A SG 11202111597UA SG 11202111597U A SG11202111597U A SG 11202111597UA SG 11202111597U A SG11202111597U A SG 11202111597UA
Authority
SG
Singapore
Prior art keywords
translation
compositions
methods
modulating splicing
splicing
Prior art date
Application number
SG11202111597UA
Inventor
Isabel Aznarez
Juergen Scharner
Original Assignee
Stoke Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stoke Therapeutics Inc filed Critical Stoke Therapeutics Inc
Publication of SG11202111597UA publication Critical patent/SG11202111597UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/33Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202111597UA 2019-04-24 2020-04-24 Methods and compositions for modulating splicing and translation SG11202111597UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838010P 2019-04-24 2019-04-24
PCT/US2020/029897 WO2020219934A1 (en) 2019-04-24 2020-04-24 Methods and compositions for modulating splicing and translation

Publications (1)

Publication Number Publication Date
SG11202111597UA true SG11202111597UA (en) 2021-11-29

Family

ID=72941425

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111597UA SG11202111597UA (en) 2019-04-24 2020-04-24 Methods and compositions for modulating splicing and translation

Country Status (15)

Country Link
US (1) US20220127612A1 (en)
EP (1) EP3958970A4 (en)
JP (1) JP2022529532A (en)
KR (1) KR20220012230A (en)
CN (1) CN114025848A (en)
AR (1) AR119722A1 (en)
AU (1) AU2020262435A1 (en)
BR (1) BR112021021047A2 (en)
CA (1) CA3134329A1 (en)
EA (1) EA202192755A1 (en)
IL (1) IL287398A (en)
MX (1) MX2021012989A (en)
SG (1) SG11202111597UA (en)
TW (1) TW202106877A (en)
WO (1) WO2020219934A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113227089A (en) 2018-10-31 2021-08-06 吉利德科学公司 Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US20230081388A1 (en) * 2020-01-28 2023-03-16 Murdoch University Antisense oligomers and methods for treating parkin-related pathologies
CN112553328B (en) * 2020-12-30 2022-06-17 浙江大学 Product for detecting gene expression level and application thereof in preparation of major depressive disorder diagnosis tool
WO2023239782A2 (en) * 2022-06-07 2023-12-14 Kicho Inc. Agents for modulating expression
WO2024009306A1 (en) * 2022-07-07 2024-01-11 Skip Therapeutics Ltd. Compositions and methods for treating primary ciliary dyskinesia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038738A2 (en) * 2000-11-09 2002-05-16 Cold Spring Harbor Laboratory Chimeric molecules to modulate gene expression
JP2010507387A (en) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド Novel siRNA and method of using the same
PL3041958T3 (en) * 2013-09-04 2020-11-02 Cold Spring Harbor Laboratory Reducing nonsense-mediated mrna decay
US20180036335A1 (en) * 2015-03-03 2018-02-08 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression
BR112019019833A2 (en) * 2017-03-24 2020-04-22 Univ Court Univ Of Edinburgh mecp2 based therapy

Also Published As

Publication number Publication date
EP3958970A1 (en) 2022-03-02
JP2022529532A (en) 2022-06-22
EP3958970A4 (en) 2023-05-31
WO2020219934A1 (en) 2020-10-29
KR20220012230A (en) 2022-02-03
TW202106877A (en) 2021-02-16
IL287398A (en) 2021-12-01
CA3134329A1 (en) 2020-10-29
EA202192755A1 (en) 2022-03-23
MX2021012989A (en) 2022-01-24
US20220127612A1 (en) 2022-04-28
BR112021021047A2 (en) 2022-03-22
AR119722A1 (en) 2022-01-05
CN114025848A (en) 2022-02-08
AU2020262435A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
ZA202004932B (en) Methods and compositions for modulating splicing
IL287398A (en) Methods and compositions for modulating splicing and translation
EP3920918A4 (en) Methods and compositions for modulating splicing
EP3920917A4 (en) Methods and compositions for modulating splicing
IL290595A (en) Compositions and methods for modulating splicing and protein expression
EP3920928A4 (en) Methods and compositions for modulating splicing
EP3920915A4 (en) Methods and compositions for modulating splicing
EP3920916A4 (en) Methods and compositions for modulating splicing
EP3920919A4 (en) Methods and compositions for modulating splicing
EP3920920A4 (en) Methods and compositions for modulating splicing
EP3585171A4 (en) Compositions and related methods for modulating endosymbionts
EP3921311A4 (en) Methods and compositions for modulating splicing
EP3920926A4 (en) Methods and compositions for modulating splicing
EP3920910A4 (en) Methods and compositions for modulating splicing
EP3938352A4 (en) Methods and compositions for modulating splicing
EP3737390A4 (en) Composition for modulating metabolism
IL307625A (en) Compositions and methods for modulating pnpla3 expression
IL286681A (en) Compounds and methods for modulating ube3a-ats
EP3870206A4 (en) Compositions and methods for modulating factor viii function
EP3927327A4 (en) Methods and devices for localizing compositions
EP3849564A4 (en) Compounds and methods for modulating cln3 expression
EP3806840A4 (en) Composition and methods for modulation of elovl2
EP3836941A4 (en) Methods and compositions for treating mucositis
IL292057A (en) Compositions and methods for inhibiting collagen loss
EP4031155A4 (en) Compositions and methods for microbiome modulation